Abcellera Biologics Inc. · NASDAQ:ABCL

Abcellera Biologics — Q1 2025 Earnings Presentation

22 slides from Abcellera Biologics's earnings presentation, May 8, 2025

Slide 2: Disclaimer
DISCLAIMER This presentation contains forward-looking statements, including statements made These statements involve risks, uncertainties and other factors that may cause pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act actual results, levels of activity, perfor
Slide 3: 2025 Priorities
2025 PRIORITIES Enter the clinic and initiate activities at clinical manufacturing facility. Q1 2025 Business Update Complete platform ABCL635 Phase 1 clinical investments by the Nominate trials initiated in 2025 additional ﬁrst half of the year ~$810M development in available candidate(s) for liqui
Slide 4: Internal Pipeline & Programs
INTERNAL PIPELINE & PROGRAMS ABCL635 is a potential ﬁrst-in-class antibody for the non-hormonal treatment of vasomotor symptoms (hot ﬂashes). Target Q1 2025 Business Update Neurokinin 3 receptor (NK3R) Target Type G protein-coupled receptor (GPCR) Indication Moderate-to-severe vasomotor symptoms (VM
Slide 5: Internal Pipeline & Programs: ABCL635
INTERNAL PIPELINE & PROGRAMS ABCL635 Initiation of Phase I clinical study NK3R Antagonist anticipated in Q3 2025 Science Commercial Opportunity Differentiation Development Path Q1 2025 Business Update ● NK3R is a GPCR involved in ● Approximately 40 million ● Potential ﬁrst-in-class ● Well-establishe
Slide 6: Commercial Opportunity
ABCL635 Commercial Opportunity VMS are highly prevalent, signiﬁcantly impact health and well-being, and are the most common reason for seeking treatment for menopause. Q1 2025 Business Update VMS are a signiﬁcant burden Millions of women seek treatment VMS are the most common symptoms of Approximate
Slide 7: Commercial Opportunity
ABCL635 Commercial Opportunity Despite effective treatments, there remains a large unmet need for many women suffering from VMS. Q1 2025 Business Update Menopause Hormone Therapy (MHT) is an effective treatment ~12% of women are ~8% of women for VMS, and the current contraindicated.1 discontinue MHT
Slide 10: Science
ABCL635 Science NK3R antagonists are effective, non-hormonal options for VMS. Treatment Q1 2025 Business Update COPYRIGHT © ABCELLERA CONFIDENTIAL 10 Proposed mechanism of action for ABCL635 based on AbCellera nonclinical data and published literature.
Slide 11: Differentiation
ABCL635 Differentiation Approved and soon-to-be-approved NK3R therapies will establish the market. Q1 2025 Business Update Fezolinetant (Veozah®) by Astellas Elinzanetant by Bayer Small molecule NK3R antagonist Small molecule NK3R and NK1R antagonist Stage Stage Approved by US FDA on May 12, 2023 ND
Slide 12: Differentiation
ABCL635 Differentiation ABCL635 is designed to offer an improved treatment option for women with moderate-to-severe VMS due to menopause. An antibody-based therapeutic may provide several beneﬁts over current non-hormonal treatments: Q1 2025 Business Update Potential for reduced toxicities & side-ef
Slide 13: Development Path
ABCL635 Development Path If successful, ABCL635 would be a differentiated product in a large and established market. Q1 2025 Business Update CTA Submission Phase I Initiation Phase I Readout safety & early eﬃcacy 2025 Q2 2025 Q3 Anticipated 2026 H1 Anticipated COPYRIGHT © ABCELLERA CONFIDENTIAL 13
Slide 14: Internal Pipeline & Programs
INTERNAL PIPELINE & PROGRAMS Initiation of Phase I clinical trials for ABCL635 & ABCL575 anticipated in Q3 2025. Q1 2025 Business Update MOLECULE TARGET THERAPEUTIC AREA STAGE CTA Submission Phase I Initiation Phase I Readout ABCL635 NK3R Endocrinology & Women’s Health 2025 Q2 2025 Q3 Anticipated 20
Slide 15: Transition to a clinical-stage biotech nearly complete.
Transition to a clinical-stage biotech nearly complete. As we shift from building our platform to using it, we are leveraging capabilities in challenging targets, including GPCRs, ion channels, and T-cell engagers to advance our pipeline. Q1 2025 Business Update Additional development candidate targ
Slide 17: We have the capabilities and the capital to execute on our strategy
~$810M in available liquidity We have the to execute on our strategy* capabilities and Q1 2025 Business Update the capital to ~$630M in total cash, cash equivalents, & marketable securities* execute on our strategy. ~$180M in total available government funding* COPYRIGHT © ABCELLERA * As of March 31
Slide 18: Continuing portfolio growth.
Continuing portfolio growth. Cumulative # of Cumulative # of Notable Updates on PARTNER-INITIATED PROGRAM STARTS MOLECULES IN THE CLINIC MOLECULES IN THE CLINIC WITH DOWNSTREAMS Q1 2025 Business Update Molecule This Quarter’s Update NBL-012 NBL-015/FL-301 Paused NBL-020 NBL-028 COPYRIGHT © ABCELLERA
Slide 19: Operating expenses reflect R&D investments.
Operating expenses reﬂect R&D investments. Revenue USD Operating Expenses USD MILESTONES RESEARCH & SALES & GENERAL & LICENSING DEVELOPMENT MARKETING ADMIN RESEARCH FEES Q1 2025 Business Update +$3.2M $39.3M $42.5M -$1.1M $17.4M $16.2M $10.0M -$0.5M $4.2M $9.8M $3.4M $2.8M COPYRIGHT © ABCELLERA $0.2
Slide 20: Net loss of $46M; equivalent to ($0.15) per share
Net loss of $46M; equivalent to ($0.15) per share (basic & diluted). Earnings USD NET EARNINGS EARNINGS PER SHARE: BASIC AND DILUTED Q1 2025 Business Update COPYRIGHT © ABCELLERA Q1 2024 Q1 2025 Q1 2024 Q1 2025 20
Slide 21: Approximately $633M in total cash, equivalents, and marketable securities.
Approximately $633M in total cash, equivalents, and marketable securities. Cash Flows USD $653M $633M Q1 2025 Business Update $469M Marketable $446M Securities Marketable Securities $25M Marketable $8M Securities (net) $6M $1M ($17M) Other $156M ($12M) $159M Cash & Cash & Equivalents Equivalents COP

AbCellera Biologics — Q1 2025 Earnings Presentation on 6ix

Abcellera Biologics — Q1 2025 Earnings Presentation

Slide 1: Q1 2025 Business Update

Slide 2: Disclaimer

Slide 3: 2025 Priorities

Slide 4: Internal Pipeline & Programs

Slide 5: Internal Pipeline & Programs: ABCL635

Slide 6: Commercial Opportunity

Slide 7: Commercial Opportunity

Slide 8: Science

Slide 9: Science

Slide 10: Science

Slide 11: Differentiation

Slide 12: Differentiation

Slide 13: Development Path

Slide 14: Internal Pipeline & Programs

Slide 15: Transition to a clinical-stage biotech nearly complete.

Slide 16: Financials Update

Slide 17: We have the capabilities and the capital to execute on our strategy

Slide 18: Continuing portfolio growth.

Slide 19: Operating expenses reflect R&D investments.

Slide 20: Net loss of $46M; equivalent to ($0.15) per share

Slide 21: Approximately $633M in total cash, equivalents, and marketable securities.

Slide 22: Thank You